Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
SSC: Factor VIII, Factor IX & Rare Coagulation Disorder
Group Pages


Factor VIII, Factor IX and Rare Coagulation Disorders

The Factor VIII, Factor IX and Rare Coagulation Disorders Subcommittee has the mission of providing a forum for consideration of practical issues related to haemophilia and other rare bleeding disorders, provide state of the art knowledge regarding the diagnosis and management of these disorders, and conduct projects that aim to standardize and harmonize available laboratory evaluation and clinical care measures for the assessment of therapeutic products and clinical outcomes.

If you are interested in the subcommittee and want to follow its activity, please click "join group" above to sign up as a member (follower). 


  • To address issues of practical importance to the research community in the field.
  • To evaluate existing data, determine issues for which data is missing or deficient, identify areas of controversy or pressing clinical need and discuss methodologic approaches to answer questions raised.
  • To create international collaborations for the purpose of planning and executing projects related to the defined needs in the field.
  • To suggest or organize collaborative studies as a result of these activities.
  • To generate, publish and distribute reports, recommendations and other documents concerning the above.
  • To develop laboratory standards, methods, and nomenclature if appropriate.


The subcommittee appoints experts into project groups with specific mandates:

  • To evaluate and standardize definition of clinical and laboratory criteria to assess the clinical severity and effectiveness of therapy
  • Standardization of the currently recommended methodologies for standard coagulation assays, global hemostasis tests and genetic analysis to assess their application in different conditions
  • To evaluate current and upcoming treatment products to prepare recommendations on their best clinical use and to foster the development of more effective products.
  • To provide recommendations for optimal and practical pre- and post- licensure clinical trial design for the new clotting factor concentrates.

Such groups work over 1-2 years, review the available information in the literature and in practice and prepare recommendations to be published as SSC communication. See specific form of each project.

If you are a member of the Society and would like to know how to participate in the work of this group, please join the group to receive updates on activity or submit an Expression of Interest Form to the Chairman or any of the Co-Chairmen. We would be pleased to learn of your interest.


Official Communication

Recent Forum Activity
Request for Proposals: WFH World Bleeding Disorders Registry
Posted by: Lacey Schmeidler, Wednesday, January 18, 2017
Forum: General Discussion
2016 Annual Minutes
Posted by: Guy Young, Wednesday, June 8, 2016
Forum: Annual Minutes
SSC 2016 Montpellier Program
Posted by: Guy Young, Monday, September 28, 2015
Forum: General Discussion
Comments requested: Safety Evaluation Study Design
Posted by: Flora Peyvandi, Tuesday, July 21, 2015
Forum: General Discussion
Comments requested: prophylaxis in boys with severe hemophilia
Posted by: Lacey Schmeidler, Monday, July 20, 2015
Forum: General Discussion
 View All Forums »

Related Group News

ISTH Presents 2020 Esteemed Career Awards
Posted in ISTH News, Monday, July 13, 2020

The ISTH has announced the commendable recipients of the 2020 ISTH Esteemed Career Awards: Francis J. Castellino, Ph.D.; Emmanuel J. Favaloro, Ph.D.; Elizabeth Gardiner, Ph.D.; ... more »

 View All News »

Johnny N. Mahlangu
Valder Arruda
Miguel A. Escobar
Sabine I. Heine
Tarek Owaidah
John J. Pasi
Savita Rangarajan


Membership Management Software Powered by YourMembership  ::  Legal
This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.